Tag: H2 receptor antagonist

  • Famotidine

    H2 receptor antagonist

    A second-generation H2 antihistamine; an acid-suppressing agent for peptic ulcers and GERD; investigated for anti-inflammatory and COVID-19 effects.

    Abstract

    Famotidine (3-({2-[(diaminomethylene)amino]-1,3-thiazol-4-yl}methylsulfanyl)-N-sulfamoyl-propanimidamide; CAS 76824-35-6; molecular formula C8H15N7O2S3; molecular weight 337.45) is a second-generation H2 receptor antagonist developed at Yamanouchi (now Astellas) and approved by the FDA in 1986 (Pepcid). The compound competitively inhibits H2 receptors on gastric parietal cells, reducing histamine-stimulated gastric acid secretion. H2 selectivity over H1 is greater than 1000-fold. Plasma half-life is approximately 2 to 4 hours; renal excretion is the principal clearance pathway. Approved indications: peptic ulcer disease, GERD, Zollinger-Ellison syndrome. The compound attracted attention during the COVID-19 pandemic after observational data suggested possible benefit; randomized controlled trials have produced mixed results, with proposed mechanisms including TMPRSS2 inhibition, sigma-1 modulation, and anti-inflammatory H2 antagonism on immune cells. Used as the canonical H2 antagonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.